Duke researchers receive grants for HIV vaccine studies
The National Institute of Allergy and Infectious Diseases (NIAID) five-year grant amounts to more than $9 million. The team led by Mary Klotman, chair of the Department of Medicine at the Duke University School of Medicine will use the grant to fund two research projects and two core facilities that are collaborating to create an effective, safe HIV vaccine using a vector delivery strategy to provoke a strong immune response.
“This grant represents an exciting collaborative effort,” Klotman said. “It combines our long-standing interest in developing integrase defective lentiviral vectors as a safe approach to persistent immunogen expression along with expertise within the Duke Human Vaccine Institute that is focused on innovative envelope immunogen design and B cells."
Another team, led by Duke University’s Department of Pediatrics assistant professor Sallie Permar, received more than $11 million from NIAID. This team includes researchers from the University of California at Davis and the University of North Carolina, and the five-year grant will finance two research projects and three core facilities to develop an infant vaccine that will eliminate pediatric HIV-1 infections.